Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations

Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, delays the increase in kidney volume (a su...

Descripción completa

Detalles Bibliográficos
Autores principales: Sans-Atxer, Laia, Joly, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797468/
https://www.ncbi.nlm.nih.gov/pubmed/29430193
http://dx.doi.org/10.2147/IJNRD.S125942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797468/
https://www.ncbi.nlm.nih.gov/pubmed/29430193
http://dx.doi.org/10.2147/IJNRD.S125942

Ejemplares similares